Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bryophyllum 50% chewable tablets
- Development stage
- Unknown
- Lead developer
- Weleda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bryophyllum 50% chewable tablets are a botanical preparation derived from the leaf press juice of *Bryophyllum pinnatum* (also known as *Kalanchoe pinnata*). Developed as an investigator-initiated trial by Christian Haslinger at the University Hospital Zurich and manufactured by Weleda AG, this herbal medicine is primarily investigated for the treatment of anxiety symptoms in women hospitalized with signs of preterm birth. The active components include bufadienolides, which are thought to modulate myometrial contractility pathways, calcium signaling, COX-2 expression, and NFκB activation. It is traditionally used in Anthroposophic Medicine for various mental and behavioral disorders.
- Brand names
- Bryophyllum 50%
- Other names
- Bryophyllum pinnatumKalanchoe pinnataBryophyllum 50% tablets
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NF-κB
Beyond the preview
Go deeper on Bryophyllum 50% chewable tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bryophyllum 50% chewable tablets.